Cover Image
市場調查報告書

CanBas Co., Ltd.:產品臨床實驗分析

CanBas Co., Ltd. - Product Pipeline Review - 2014

出版商 Global Markets Direct 商品編碼 200933
出版日期 內容資訊 英文 29 Pages
訂單完成後即時交付
價格
Back to Top
CanBas Co., Ltd.:產品臨床實驗分析 CanBas Co., Ltd. - Product Pipeline Review - 2014
出版日期: 2014年03月31日 內容資訊: 英文 29 Pages
簡介

CanBas Co., Ltd.是以腫瘤細胞週期為目標研究開發新型治療藥物的臨床階段生醫藥品企業。

本報告針對CanBas Co., Ltd.治療藥開發臨床實驗現況與各開發階段比較分析、提供藥劑標的、作用程序、投藥過程、分子種類分類治療藥評價、最新企業新聞發表、後期階段與中止方案相關資料。

CanBas Co., Ltd.基本情報

CanBas Co., Ltd.概要

  • 主要情報
  • 企業情報

CanBas Co., Ltd.:R&D概要

  • 主要治療範圍

CanBas Co., Ltd.:臨床實驗回顧

  • 開發階段分類臨床實驗產品
  • 單劑產品
  • 併用療法模式

CanBas Co., Ltd.:臨床實驗產品概況

  • 測試階段臨床實驗產品
    • 第II期產品/併用療法模式
    • 第I期產品/併用療法模式
  • 初期階段臨床實驗產品
    • 前臨床階段產品/併用療法模式
    • 創藥中產品/併用療法模式

CanBas Co., Ltd.:藥劑檔案

  • CBP-501 + (cisplatin) + (pemetrexed disodium)
  • CBP-501 + (cisplatin)
  • CBS-9106
  • CBS-2400

CanBas Co., Ltd.:臨床實驗分析

  • 標的分類
  • 投藥通路分類
  • 分子種類分類
  • 作用排序分類

CanBas Co., Ltd.:最近臨床實驗動向

CanBas Co., Ltd.:總公司與子公司所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC04738CDB

Global Markets Direct's, 'CanBas Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the CanBas Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CanBas Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of CanBas Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of CanBas Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the CanBas Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate CanBas Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of CanBas Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the CanBas Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of CanBas Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of CanBas Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of CanBas Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • CanBas Co., Ltd. Snapshot
    • CanBas Co., Ltd. Overview
    • Key Information
    • Key Facts
  • CanBas Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • CanBas Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • CanBas Co., Ltd. - Pipeline Products Glance
    • CanBas Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • CanBas Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • CanBas Co., Ltd. - Drug Profiles
    • CBP-501 + [cisplatin] + [pemetrexed disodium]
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBP-501 + [cisplatin]
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBS-9106
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CBS-2400
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • CanBas Co., Ltd. - Pipeline Analysis
    • CanBas Co., Ltd. - Pipeline Products by Target
    • CanBas Co., Ltd. - Pipeline Products by Route of Administration
    • CanBas Co., Ltd. - Pipeline Products by Molecule Type
    • CanBas Co., Ltd. - Pipeline Products by Mechanism of Action
  • CanBas Co., Ltd. - Recent Pipeline Updates
  • CanBas Co., Ltd. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • CanBas Co., Ltd., Key Information
  • CanBas Co., Ltd., Key Facts
  • CanBas Co., Ltd. - Pipeline by Indication, 2014
  • CanBas Co., Ltd. - Pipeline by Stage of Development, 2014
  • CanBas Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • CanBas Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014
  • CanBas Co., Ltd. - Phase II, 2014
  • CanBas Co., Ltd. - Phase I, 2014
  • CanBas Co., Ltd. - Preclinical, 2014
  • CanBas Co., Ltd. - Discovery, 2014
  • CanBas Co., Ltd. - Pipeline by Target, 2014
  • CanBas Co., Ltd. - Pipeline by Route of Administration, 2014
  • CanBas Co., Ltd. - Pipeline by Molecule Type, 2014
  • CanBas Co., Ltd. - Pipeline Products by Mechanism of Action, 2014
  • CanBas Co., Ltd. - Recent Pipeline Updates, 2014

List of Figures

  • CanBas Co., Ltd. - Pipeline by Top 10 Indication, 2014
  • CanBas Co., Ltd. - Pipeline by Stage of Development, 2014
  • CanBas Co., Ltd. - Monotherapy Products in Pipeline, 2014
  • CanBas Co., Ltd. - Combination Treatment Modalities in Pipeline, 2014
  • CanBas Co., Ltd. - Pipeline by Top 10 Target, 2014
  • CanBas Co., Ltd. - Pipeline by Top 10 Route of Administration, 2014
  • CanBas Co., Ltd. - Pipeline by Top 10 Molecule Type, 2014
  • CanBas Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2014
Back to Top